Roivant Wins Approval for the First Oral Dermatomyositis Drug. How Large is the Opportunity?

Roivant Sciences Ltd. (NASDAQ:ROIV) and partner Priovant Therapeutics have secured FDA approval for Lisraya, the first oral treatment for dermatomyositis, which is a rare condition that causes painful skin rashes and progressive muscle weakness.

The approval gives patients an oral alternative in a disease with limited targeted treatment options. It also creates a new commercial opportunity for Roivant, although the condition affects fewer than 5,000 people in the United States and Priovant has not yet disclosed the drug’s price.

Bull Case

Lisraya’s status as the first oral treatment for dermatomyositis provides the clearest argument for its potential adoption. Octapharma’s intravenous Octagam 10% is the only other modern targeted therapy approved by the FDA for the condition, meaning Lisraya introduces a different method of administration for eligible patients. Priovant CEO Ben Zimmer also described Lisraya as the first treatment to target immune pathways connected to the disease. According to Zimmer, the drug demonstrated benefits involving the skin, muscles, and physical function while reducing patients’ reliance on steroids.

That steroid-sparing effect could be important because steroids are commonly used to manage dermatomyositis but can cause side effects when taken over extended periods. Roivant and Priovant said Lisraya improved both skin and muscle symptoms in the late-stage study while allowing some patients to reduce or discontinue steroids.

The trial results provide clinical support for the approval. Patients receiving a daily 30-milligram dose of brepocitinib, the drug’s chemical name, achieved a mean total improvement score of 46.5 after 52 weeks, compared with 31.2 among patients receiving a placebo. The difference was statistically significant, and the companies reported that benefits appeared as early as week four. Those results suggest the treatment’s effect extended across the one-year study rather than appearing only at the final assessment.

The commercial expectations are also considerable. J.P. Morgan analyst Brian Cheng forecasts that Lisraya could generate more than $2 billion in peak annual US sales for dermatomyositis alone by the early 2030s. Cheng described the condition as underappreciated within inflammation and immunology but potentially attractive for Roivant commercially. Investors initially responded positively to the approval, with Reuters reporting that Roivant shares rose 2% to $37.58 in afternoon trading following the FDA decision.

Bear Case

The small patient population creates the most obvious commercial uncertainty for investors in this scenario. According to the National Institutes of Health, dermatomyositis affects fewer than 5,000 people in the United States, and reaching a multibillion-dollar sales level within such a limited population would depend on several factors, such as pricing, patient identification, treatment eligibility, and sustained adoption.

The companies have also not provided commercial-launch figures in the supplied information. FDA approval establishes that Lisraya can be marketed for dermatomyositis, but it does not show how quickly physicians will prescribe it or how many patients will receive treatment.

Conclusion

Lisraya gives Roivant and Priovant an important first-mover position as the only oral treatment approved for dermatomyositis. Its statistically significant late-stage results and reported benefits across skin, muscle function, and steroid use provide a credible foundation for the launch.

Its commercial scale remains uncertain, however. With fewer than 5,000 US patients and pricing still undisclosed, investors should treat the $2 billion peak-sales estimate as an analyst forecast rather than an established outcome. Approval is a major milestone for the company, and pricing and adoption will determine its ultimate value.

READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth? 

This article is originally published at Insider Monkey.